Full Breakdown
Karnataka Fake-Medicine Racket: SIT Expands Arrests and Probes Hospital Purchases
By Drooid · · How we work
Core Event – Seventh Accused Nabbed in Chennai
On Tuesday, the Special Investigation Team (SIT) arrested Balasubramanian in Chennai, the seventh person taken into custody in the inter-state fake-medicine investigation. SIT sources say Balasubramanian ran a dummy company that received consignments from prime accused R Prashanth and suspect Veeresh, then supplied the spurious drugs in Chennai and nearby areas. The arrest followed information obtained during the interrogation of Prashanth, who remains in police custody.
Background & Context – Earlier Raids and Alleged Kingpin
The probe began after the Karnataka Food and Drug Administration (FDA) raided a farmhouse in Bidadi, Bengaluru South district on 18 August, uncovering counterfeit medicines and industrial machinery valued at roughly Rs 5.05 crore. Investigators identified Prashanth Babu as the alleged kingpin; he was detained at Bengaluru airport after a month-long manhunt that traced his travel to Turkey and Azerbaijan. His arrest triggered a series of detentions, including the recent capture of Balasubramanian.
Timeline
| Date | Event |
|---|---|
| 18 August | FDA raid discovers spurious drugs and machinery at Bidadi farmhouse. |
| Early September | Prashanth Babu detained at Bengaluru airport after fleeing abroad. |
| Tuesday (date not disclosed) | Balasubramanian arrested in Chennai, seventh suspect. |
| 22 September | Pfizer issues a statement on its cooperation with authorities. |
Data & Statistics
- Seized assets: Approximately Rs 5.05 crore worth of counterfeit drugs and related equipment.
- Licensing actions: Licences of 17 pharmaceutical distributors cancelled; 8 suspended; the licence of Pfizer C & F on Bengaluru’s outskirts also suspended.
- Counterfeit characteristics: Fake batches imitated Pfizer’s imported products, bore non-functional QR/scanning codes, and contained either no active ingredients, wrong substances, or toxic compounds, posing a fatal health risk.
Official Statements & Responses
- The Drugs Control Department has sought Union-government assistance to examine measures for regulating and capping medicine prices, citing concerns over unusually low purchase costs by hospitals.
- The Pfizer C & F facility’s licence suspension was confirmed by the company, which said it is cooperating with investigators.
On-the-Ground Reports – Hospital Scrutiny
Hospitals in Bengaluru that purchased the suspect medicines have received notices demanding details of their procurement processes. Investigators are probing whether the hospitals were aware of the drugs’ origins, whether mandatory procedures were bypassed, and why the purchases were made at lower prices.
Conflicting Reports & Gaps
- Role of Balasubramanian: SIT sources describe him as the director of a dummy company facilitating distribution, while police officials have not yet confirmed this role.
- International dimension: The SIT has not ruled out an overseas network, yet concrete evidence of foreign links remains unverified.
Verbatim Quotes
- “We have been working with the authorities for the past month since the matter of counterfeit medicines was brought to our attention,” — Pfizer
What’s Next – Ongoing Probes and Potential Regulation
The SIT is expanding its investigation to trace overseas financial and business connections of the accused, examine statements of the six previously arrested suspects, and determine the full scope of the distribution chain. Authorities are also reviewing compliance by hospitals that bought the counterfeit drugs and are considering regulatory steps to prevent future price manipulation and ensure drug safety.
